Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

SSTR agonist

DRUG CLASS:

SSTR agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval lanreotide prolonged-release subcutaneous Sensitive : A1	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval lanreotide prolonged-release subcutaneous Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	DG3173 Sensitive: A2 - Guideline DG3173 Sensitive : A2	DG3173 Sensitive: A2 - Guideline DG3173 Sensitive : A2
SSTR5 expression	Neuroendocrine Tumor	SSTR5 expression	Neuroendocrine Tumor	octreotide Sensitive: C3 – Early Trials octreotide Sensitive : C3	octreotide Sensitive: C3 – Early Trials octreotide Sensitive : C3
SSTR2 expression	Neuroendocrine Tumor	SSTR2 expression	Neuroendocrine Tumor	octreotide Sensitive: C3 – Early Trials octreotide Sensitive : C3	octreotide Sensitive: C3 – Early Trials octreotide Sensitive : C3
BRAF wild-type + NRAS wild-type	Melanoma	BRAF wild-type + NRAS wild-type	Melanoma	pasireotide Sensitive: C3 – Early Trials pasireotide Sensitive : C3	pasireotide Sensitive: C3 – Early Trials pasireotide Sensitive : C3
SSTR5 expression	Non Small Cell Lung Cancer	SSTR5 expression	Non Small Cell Lung Cancer	paclitaxel + octreotide Sensitive: D – Preclinical paclitaxel + octreotide Sensitive : D	paclitaxel + octreotide Sensitive: D – Preclinical paclitaxel + octreotide Sensitive : D
SSTR2 expression	Non Small Cell Lung Cancer	SSTR2 expression	Non Small Cell Lung Cancer	paclitaxel + octreotide Sensitive: D – Preclinical paclitaxel + octreotide Sensitive : D	paclitaxel + octreotide Sensitive: D – Preclinical paclitaxel + octreotide Sensitive : D